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Abstract
Background: The aim was to determine if effects from smoking on lung function measured over
11 years differ between men and women.
Methods: In a prospective population based cohort study (Swiss Study on Air Pollution and Lung
Diseases in Adults) current smokers in 1991 (18 – 60 yrs) were reassessed in 2002 (n = 1792).
Multiple linear regression was used to estimate effects from pack-years of cigarettes smoked to
1991 and mean packs of cigarettes smoked per day between 1991 and 2002 on change in lung
volume and flows over the 11 years.
Results: In both sexes, packs smoked between assessments were related to lung function decline
but pack-years smoked before 1991 were not. Mean annual decline in FEV1 was -10.4 mL(95%CI -
15.3, -5.5) per pack per day between assessments in men and -13.8 mL(95%CI-19.5,-8.1) in women.
Decline per pack per day between 1991 and 2002 was lower in women who smoked in 1991 but
quit before 2002 compared to persistent smokers (-6.4 vs -11.6 mL, p = 0.05) but this was not seen
in men (-14.3 vs -8.8 mL p = 0.49). Smoking related decline was accelerated in men and women
with airway obstruction, particularly in women where decline in FEV1 was three fold higher in
participants with FEV1/FVC<0.70 compared to other women (-39.4 vs -12.2 mL/yr per pack per
day, p < 0.002).
Conclusion: There are differences in effects from smoking on lung function between men and
women. Lung function recovers faster in women quitters than in men. Women current smokers
with airway obstruction experience a greater smoking related decline in lung function than men.
Published: 26 May 2005
Respiratory Research 2005, 6:45 doi:10.1186/1465-9921-6-45
Received: 28 January 2005
Accepted: 26 May 2005
This article is available from: http://respiratory-research.com/content/6/1/45
© 2005 Downs et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2005, 6:45 http://respiratory-research.com/content/6/1/45
Page 2 of 10
(page number not for citation purposes)
Background
Cigarette smoking is the most well known risk factor for
accelerating lung function decline in adults [1]. Until
recently, smoking prevalence and intensity was greater in
men than in women; but there is now evidence that
women are starting to smoke as much as men [1,2]. At
present, there is no consensus whether women are more
sensitive to effects from cigarette smoke than men [1-8].
Relatively few large studies have compared effects from
smoking between men and women and results have not
been consistent between studies. A greater decline in lung
function per pack-year in women compared to men was
reported by Chen et al but the converse was found by Xu
et al [5,6]. Prescott et al reported slightly higher coeffi-
cients for decline in FEV1 per pack-year in women com-
pared to men and Connett et al reported similar rates of
decline in men and women but a swifter regain in FEV1 in
women who quit smoking [4,7].
Smoke related lung damage is characterised by inflamma-
tion, airway obstruction and destruction of the lung
parenchyma [9,10]. Underlying lung characteristics can
vary and there is some evidence that smokers differ in
their predisposition to develop predominantly emphy-
sema or bronchitis [11,12]. Predispositions between men
and women may vary because of differences in lung mor-
phology that modify the dispersion and deposition of cig-
arette smoke or differences in homeostatic processes
affecting the efficacy of lung clearance and recovery after
smoking cessation [13-15].
The strongest effects from smoking have been consistently
measured in current smokers and detrimental effects have
been shown to reduce with time from cessation [1,16].
The vast majority of surveys of effects from smoking on
lung function have focused on FEV1 (forced expiratory
volume in one second). However, effects may be also be
revealed in other measures of lung function such as FEF25
(forced expiratory flow at 25% of lung volume) that may
better reflect damage to the small airways. An argument
for not investigating lung flow rates has been the large
inter-subject variability in the rates which prejudices
against precise estimation of effects in cross-sectional
analyses. In a cohort study however, the inter-participant
differences become less important because each subject
serves as its own control.
The Swiss Study on Air Pollution and Lung Diseases in
Adults (SAPALDIA) is a prospective population based
cohort study initiated in 1991 and designed to measure
long term effects of air pollution and other risk factors on
respiratory health [17]. In cross-sectional analyses, associ-
ations were found between levels of lung function and
exposure to air pollutants as well as to cigarette smoke
[18-20]. Eleven years later, participants have been re-
examined using the same methodology. Lung volumes
and flows as well as smoking history were measured in
1991 and 2002. The aim of the present analysis is to assess
the long term effects from smoking on change in lung
function and to compare effects between men and
women. The sample examined is current smokers at the
time of the first assessment (1991). Effects from smoking
up to 1991 and between 1991 and 2002 (SAPALDIA 1
and 2) are compared for lung flows (FEF25, FEF50 and
FEF75) as well as for FEV1.
Methods
SAPALDIA is a multi-centre population based prospective
cohort study. The study participants were recruited from
random population samples from local registries of
inhabitants from eight areas of Switzerland. The eight
areas were chosen to represent the variety of environmen-
tal conditions found in Switzerland concerning geogra-
phy, climate, degree of urbanisation and air pollution. To
meet the selection criteria, individuals had to be 18 to 60
years of age by December 1990, local residents for at least
three years and Swiss nationals or foreigners with a resi-
dence permit. There were 9651 participants in SAPALDIA
1 representing 60% of the eligible sample. Participants in
SAPALDIA 1 were invited for re-examination between
2001 and 2003. Methods in SAPALDIA have been
described in detail [17,21]. Ethical approval for the study
was given by the Regional Ethics Commission for Clinical
Medicine (Swiss Academy of Medical Sciences) and each
centres' regional ethics committee.
Identical protocols for spirometry that complied with
American Thoracic Society recommendations, were fol-
lowed in SAPALDIA 1 and 2 [22,23]. The highest values
for forced vital capacity (FVC) and FEV1 of an acceptable
trial were selected. Measures of expiratory flows (FEF75,
FEF50 and FEF25) were taken from the flow-volume curve
with the highest sum of FVC and FEV1. Participants were
requested not to use beta-2-agonists or anticholinergic
inhalers four hours prior to and long-acting beta agonists,
oral beta-2-agonists, theophyline or oral antimuscarinic
medication eight hours prior to the time of appointment
of the examination.
Information about smoking and other risk factors was
gathered through an interview administered question-
naire based on the European Community Respiratory
Health Survey (ECRHS) questionnaire [24]. Three catego-
ries of smoking status were derived: current smoker,
former smoker and never smoker. Smokers had to have
smoked more than 20 packs of cigarettes or more than
360 g of tobacco. 'Current' smokers were smokers who
had smoked within the month before the interview. Other
participants with validated smoking histories were classi-
fied as former smokers. Cumulative cigarette smokingRespiratory Research 2005, 6:45 http://respiratory-research.com/content/6/1/45
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exposure was summarised into two variables: pack-years
to SAPALDIA 1 based on responses at SAPALDIA 1 and
mean packs of cigarettes smoked per day between SAPAL-
DIA 1 and 2 (packs per day) based on responses at SAPA-
LDIA 1 and 2. Pack-years were calculated as years of
smoking multiplied by number of cigarettes per day
divided by 20.
Participants were asked not to smoke in the hour before
the examination and this was validated in both surveys by
measuring carbon monoxide (CO) concentration in
exhaled breath using a EC 50 Micro-Smokerlizer Bedfont
measuring device.
Statistical analysis
The effect of smoking on mean annual change in FEV1,
FEF25, FEF50 and FEF75 between surveys was analysed by
multiple linear regression. The main covariates investi-
gated were pack-years to SAPALDIA 1 and mean packs per
day smoked between surveys. All analyses were confined
to subjects classified as current smokers at SAPALDIA 1.
Separate models analyses were conducted for men and
women. Covariates tested in the regression models, other
than the variables "pack-year" and "packs per day"
included study area, atopy, childhood respiratory infec-
tion before age five, maternal smoking, paternal smoking,
education, current and ever exposure to dust and fumes at
work, age at start of smoking, inhaler or not, pipe smoker,
solely non-cigarette smoker, body mass index (BMI),
weight at baseline, change in weight, change in BMI
between surveys and years since quitting. Predictors in
each model are shown in the footnote to table 3. Baseline
lung function parameters were included in all models
because we could not assume that the change in lung
function would be the same for all lung volumes and
because we wanted to absorb effects from smoking up to
baseline (SAPALDIA 1). However, effects were also re-
examined in models that did not contain baseline lung
function covariates. For each continuous covariate, we
tested whether a linear, quadratic or cubic polynomial
best described the relation with change in lung function.
Statistical tests for interaction were conducted to deter-
mine differences in effects from smoking between men
and women and between subjects with FEV1/FVC greater
or less than 0.70.
Fourteen men and 11 women were excluded from the
regression analyses because they had been classified as
current smokers at SAPALDIA 1 and claimed to be never
smokers at SAPALDIA 2. Five men and three women were
excluded because they claimed to be former smokers at
SAPALDIA 2 but had expired CO concentrations greater
than 10 ppm (median 15.5, IQR 11.5–20). There were 53
women and 99 men respectively for whom information
on pack-years or packs smoked were missing and 74 par-
ticipants with missing flow data.
Regression diagnostics were conducted to identify influ-
ential data. Sensitivity analyses were conducted to exam-
ine effects after eliminating points with high leverage or
large residuals and to assess possible biases due to missing
information about numbers of cigarettes smoked. Analy-
ses were conducted using STATA SE version 8.0 (Stata-
Corp, Texas, 77845 USA).
Results
Of the 3232 current smokers in 1991 at SAPALDIA 1,
1792 (55%) participants provided spirometry and smok-
ing information from both surveys (see Table 1). Smokers
who did not participate in SAPALDIA 2 had slightly worse
lung function at baseline. Male smokers were more likely
than women to show evidence of airway obstruction
(FEV1/FVC ratio<0.70) than female smokers and had
accumulated more pack-years. The period of follow-up
was the same in men and women (median 10.9 years, IQR
10.8–11.0).
Approximately 30 % of men and women who were cur-
rent smokers in 1991 had quit by 2002. Men had accumu-
lated more pack-years between surveys but were more
likely to have quit smoking (see Table 2). Median years
since quitting amongst quitters were 5.5 (IQR 2.1 to 9.7)
in men and 4.2 (IQR 2.2 to 9.2) in women. The correla-
tion coefficient between pack-years smoked before 1991
and pack-years smoked between surveys was 0.55 in men
and 0.68 in women. Mean weight change was +5.4 kg in
men and +5.5 kg in women. Absolute mean declines in
lung function were greater in men compared to women
except for FEF25. After controlling for mean lung size or
flow measured in 1991 differences in change between
men and women became less significant except for FEF25.
Mean percent change in FEF25 from baseline was -3.4
(5%CI -3.6, -3.2) in women and -2.8 (95%CI -3.0, -2.7)
in men. The greatest inter-subject variability in change was
observed for FEF75 (forced expiratory flow at 75% of lung
volume).
The adjusted effects from pack-years of cigarettes smoked
to 1991 and per pack smoked per day per year between
1991 and 2002 are shown in table 3. Removal of baseline
lung function variables from models made only small dif-
ferences to effect estimates. Point estimates for effects
from pack-years were stable in all models for both men
and women after removal of influential observations.
In men, there was no association between pack-years to
1991 and change in lung function between 1991 and
2002 (see Table 3). The covariate for pack-year was
retained as a linear term in all models however, because itRespiratory Research 2005, 6:45 http://respiratory-research.com/content/6/1/45
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influenced effect estimates for packs per day between
1991 and 2002. Restricting models to participants who
were current smokers in both surveys made no difference
to the effect estimates for pack-years to 1991.
In contrast to men, significant non-linear relations
between annual change in lung function and pack-years
smoked to 1991 were found in women (see Tables 3, 4
and 5). The polynomial terms were highly significant. A
non-linear relation between pack-years and change in
FEF25 was also seen in women that was not seen in men.
Lung function decline was strongly associated with packs
of cigarettes smoked per day between 1991 and 2002 in
both men and women (see Table 3). Point estimates were
of a similar magnitude in both sexes with an additional
mean annual decline in FEV1  per pack of cigarettes
smoked per day of -10.4 mL in men and -13.8 mL in
women. Similar patterns to those seen for FEV1, of
stronger effects from recent smoking than from past, were
found in the change in flows and especially for FEF25
(forced expiratory flow at 25% of lung volume).
Table 1: Characteristics of current smokers in 1991 (SAPALDIA 1)
Participants in SAPALDIA 1 and 2* Participants only in SAPALDIA 1 †
Characteristic measured in 1991 Men (n = 978) Women (n = 814) Men (n = 844) Women (n = 596)
Median age [yrs] (IQR) 41.8 (32.1, 49.6) 38.4 (31.0, 46.6) 40.2 (30.7, 49.2) 39.8 (30.8, 47.3)
Mean height [cm] (SD) 175.2 (6.8) 163.2 (6.6) 174.4 (7.2) 163.4 (6.5)
Mean weight [kg] (SD) 76.7 (11.1) 59.6 (9.5) 75.4 (11.7) 61.8 (13.8)
% atopic 23.2 18.4 22.6 22.5
% severe respiratory infection as an infant 6.2 9.5 5.3 6.7
% basic schooling only 13.8 17.7 22.1 22.1
% exposed to dust & fumes at work 45.5 25.1 48.2 25.2
% mother smoked 13.4 18.3 14.4 22.4
% father smoked 61.3 58.5 63.1 59.9
Median cig/day (IQR) 20 (14, 30) 20 (10, 20) 20 (15, 30) 20 (10, 23)
Median pack-years (IQR) 20.6 (8.3, 36.1) 14.4 (6.4, 25.0) 21.3 (9.1, 38.2) 15.9 (7.2, 26.7)
% inhaler 82.9 88.8 87.9 85.9
Median age started smoking [yrs] (IQR) 18 (16, 20) 18 (16, 20) 18 (16, 20) 18 (16, 20)
Median carbon monoxide [ppm] (IQR) 19 (9, 30) 16 (8, 28) 24 (13, 35) 20 (10, 30)
Mean FVC [mL] (SD) 5238 (861) 3868 (624) 5079 (874) 3745 (631)
Mean FEV1[mL] (SD) 4031 (759) 3099 (552) 3902 (837) 2957 (575)
Mean FEF25[mL/s] (SD) 1535 (793) 1427 (748) 1562 (871) 1325 (734)
Mean FEF50[mL/s] (SD) 4535 (1529) 3807 (1127) 4421 (1641) 3600 (1182)
Mean FEF75[mL/s] (SD) 7876 (2133) 5816 (1479) 7528 (2370) 5536 (1516)
% FEV1/FVC≤ 0.7 15.9 9.3 19.8 14.1
*With information on spirometry and smoking
† Includes participants in SAPALDIA 2 who provided information on smoking but no spirometry IQR = inter-quartile range
Table 2: Smoking and lung function measured in 2002 (SAPALDIA 2)
Men n = 978 Women n = 814
% new former smokers 31.7 27.2
Median pack-years between 1991 and 2002 (IQR) 9.0 (3.8, 13.5) 7.6 (4.0, 11.0)
% inhaler 84.7 90.3
Mean annual change in:
FVC [mL] (SD) -32.6 (48.9) -20.7 (35.8)
FEV1[mL] (SD) -43.8 (36.6) -34.7 (27.2)
FEF75[mL/s] (SD) -59.1 (167.4) -34.1 (121.6)
FEF50[mL/s] (SD) -78.7 (90.9) -70.1 (71.9)
FEF25[mL/s] (SD) -46.9 (47.3) -51.8 (45.7)Respiratory Research 2005, 6:45 http://respiratory-research.com/content/6/1/45
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Whereas the decline in FEV1 per pack per day smoked
between surveys was smaller in women quitters compared
to women continuing smokers; there was no difference in
effect estimates for men (see Table 4) (p = 0.12 for differ-
ence in effect of pack-years in quitters between men and
women). Inclusion of a variable for years since quitting
into the models for quitters reduced effect estimates for
change in FEV1 per pack per day to -13.4 mL/yr (95%CI -
1.9 to 2.2) in men and -0.7 mL/yr (-0.6 to 1.9) in women
thereby magnifying the difference in effects between men
and women quitters (p = 0.07). Difference in effect esti-
mates between women persistent smokers and quitters
was also increased by adjusting for years since quitting (p
= 0.02).
Decline in lung function per pack per day between surveys
was greater in men and women with a reduced FEV1/FVC
at baseline compared to other participants (see Table 5
and Figure 1). The difference in effect per packs per day on
annual change in FEV1 between women with and without
FEV1/FVC <0.70 was three fold and highly significant (p <
0.002). A smaller difference in the effect from cigarette
smoking between men with and without FEV1/FVC <0.70
was seen (p = 0.07). The p value for the difference in
effects between men and women with a reduced FEV1/
FVC was 0.05.
Discussion
Using quantitative information on cigarettes smoked dur-
ing two time periods, we show similarities and differences
in the effect of smoking on lung function decline between
men and women. Decline due to smoking is strongly
related to recent exposure and to a similar magnitude in
men and women overall. However, we found evidence
that the facility for recovery from past smoking is greater
in women quitters. In both men and women, effects from
recent smoking were more detrimental to lung function in
individuals with pre-existing airway obstruction. How-
Table 3: Mean annual change in lung function per pack-year to 1991 and per pack of cigarettes smoked per day between 1991 and 2002 
in women and men
Term Annual change per pack-year to 1991 Annual change per packs per day between 1991 and 2002
Coef 95%CI p value Coef 95%CI p value
FEV1[mL]
Men (n = 840) Linear -0.1 -0.2, 0.1 0.50 -10.4 -15.3, -5.5 <0.001
Women (n = 735) Linear 1.3 0.7, 2.0 <0.001 -13.8 -19.5, -8.1 <0.001
Quadratic -0.04 -0.06, -0.02 <0.001 na na na
Cubic 0.0004 0.0002, 
0.0005
<0.001 na na na
FEF75[mL/s]
Men (n = 798) Linear -0.6 -1.4, 0.1 0.11 -35.1 -57.5, -12.7 0.002
Women (n = 697) Linear -0.2 -1.0, 0.7 0.64 -18.6 -42.7,4.9 0.12
FEF50[mL/s]
Men (n = 825) Linear -0.2 -0.6, 0.2 0.31 -22.4 -34.5, -10.3 <0.001
Women (n = 697) Linear 0.2 -0.3, 0.8 0.31 -31.3 -46.1, -16.5 <0.001
FEF25[mL/s]
Men (n = 823) Linear -0.05 -0.1, 0.1 0.59 -8.9 -14.5, -3.4 <0.002
Women (n = 731) Linear 1.1 0.2, 1.9 0.01 -10.0 -17.3, -2.8 0.007
Quadratic -0.03 -0.6, -0.01 0.01 na na na
Cubic 0.0003 0.00005, 
0.0005
0.006 na na na
na: no association with polynomial terms
Covariates other than smoking variables:
Models for Men:
FEV1 FEV1, FEV1
2, age, height, atopy, weight change, current exposure to dust & fumes at work, study area
FEF75 FEF75, FEF75
2, age, age2, atopy, maternal smoking, study area
FEF50 FEF50, age, weight, study area
FEF25 FEF25, FEF25
2, FEF25
3, age, weight, weight change, study area
Models for Women:
FEV1 FEV1, FEV1
2, age, age2, height, height2, atopy, weight change, study area
FEF75 FEF75, FEF75
2, FEF75
3 age, paternal smoking, study area
FEF50 FEF50, age, weight, weight change, paternal smoking, study area
FEF25 FEF25, age, age2, height, weight, weight change, study areaRespiratory Research 2005, 6:45 http://respiratory-research.com/content/6/1/45
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ever, the strongest effects from smoking were seen in the
additional decline in FEV1 in women with a reduced FEV1/
FVC ratio.
The mean unadjusted changes in lung function over the
11-year follow-up of the SAPALDIA cohort study are
broadly consistent with changes reported elsewhere
[6,25,26]. Average annual declines in FEV1 in SAPALDIA
were higher than those for smokers in the ECRHS
although lower than those reported in the Lung Health
Study. Mean annual declines in FEV1 were -35 mL in men
and -27 mL in women persistent smokers in ECRHS but
participants were on average younger than the SAPALDIA
participants (mean age 34 years versus 40 at study entry).
Mean annual declines of -66 ml and -54 mL in FEV1 were
reported for men and women continuing smokers respec-
tively in the Lung Health Study (LHS). However, the LHS
participants were older (35–60 years versus 18–60 years),
had chronic obstructive airways disease and also reported
heavier smoking (mean of 30 cigarettes per day versus 20
in SAPALDIA) at study entry [26]. In the Six Cities study,
effect estimates for mean annual change in FEV1 per pack
smoked in men (-12.6 ml per pack per day, 95%CI -9.7, -
15.5) were similar to the effects we found in men but esti-
mates in women (-7.2 ml per pack per day, 95%CI -9.5, -
4.8) were lower than ours. However, the effects of smok-
Table 4: Mean annual change in FEV1 per pack-year to 1991 and per pack of cigarettes smoked per day between 1991 and 2002 in 
quitters* and persistent smokers
Term Annual change in mL per pack-year to 1991 Annual change in mL per packs per day between 1991 and 2002
Coef 95%CI p value Coef 95%CI p value
Quitters†
Men (n = 245) Linear -0.1 -0.4, 0.3 0.78 -14.3 -22.6, -6.0 0.001
Women (n = 179) Linear 1.5 0.3, 2.6 0.01 -6.4 -17.6, 4.6 0.25
Quadratic -0.04 -0.08,-0.01 0.01 na na na
Cubic 0.0004 0.0001,0.0006 0.006 na na na
Persistent smokers†
Men (n = 595) Linear -0.1 -0.3, 0.12 0.41 -9.0 -15.4, -2.5 0.006
Women (n = 556) Linear 1.4 0.5, 2.3 0.001 -11.6 -19.8, -3.5 0.005
Quadratic -0.06 -0.08, -0.02 <0.001 na na na
Cubic 0.0006 0.0003, 0.0008 <0.001 na na na
*Quitters were current smokers in 1991 who had stopped smoking by 2002.
† P values for interaction between persistent smoking and quitting with packs per day: men = 0.49 women = 0.05
na: no association with polynomial terms
Effects estimated from regression models with same covariates as in Table 3
Table 5: Mean annual change in FEV1 per pack-year to 1991 and per pack of cigarettes smoked per day between 1991 and 2002 by 
degree of airway obstruction in 1991
Term Annual change in mL per pack-year to 1991 Annual change in mL per packs per day between 1991 and 2002
Coef 95%CI p value Coef 95%CI p value
FEV1/FVC>0.7†
Men (n = 692) Linear -0.1 -0.3, 0.1 0.48 -8.8 -14.1, -3.5 0.001
Women (n = 659) Linear 1.4 0.8, 2.0 <0.001 -12.2 -18.1, -6.4 <0.001
Quadratic -0.04 -0.06, -0.03 <0.001 na na na
Cubic 0.0004 0.0002, 0.0005 <0.001 na na na
FEV1/FVC<0.7†
Men (n = 127) Linear -0.2 -0.6, 0.2 0.36 -12.9 -25.0, -0.7 0.04
Women (n = 67) Linear -0.9 -2.2, 0.5 0.21 -39.4 -69.1, -9.6 0.01
Quadratic 0.02 0.01, 0.04 0.009 na na na
† P values for interaction between high and reduced FEV1/FVC with packs per day: men = 0.07 women = 0.002
na: no association with polynomial terms
Effects estimated from regression models with same covariates as in Table 3Respiratory Research 2005, 6:45 http://respiratory-research.com/content/6/1/45
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ing prior to follow-up and smoking during the follow-up
period (3–6 years) were summarized into one variable of
packs smoked and were not examined separately in the Six
Cities study [6].
In both men and women, mean packs smoked per day
between 1991 and 2002 were linearly associated with
decline in lung function over the time period but pack-
years to 1991 were not. The point estimates for annual
change in lung function per pack per day in the most
recent 11 years were similar in men and women with no
evidence of airway obstruction. There was some evidence
that men and women with poor lung function and who
smoked heavily were less likely to participate in the sec-
ond survey and this may be part of the explanation why
we did not measure a negative effect from earlier pack-
years.
Pack-years of cigarettes smoked before the 1991 were
associated with non-linear changes in FEV1 and FEF25
between surveys in women. The polynomial terms were
highly significant (p < 0.001) implying multiple testing is
unlikely to be an explanation. Possibly women, as a
group, have a more heterogeneous response to smoking
than men. We found evidence that suggested that women
both recover more swiftly after quitting smoking than
men but also that women with airway obstruction are
more vulnerable to effects from smoking.
Relation between annual decline in FEV1 and mean packs/day smoked between 1991 and 2002 from regression models  reported in Table 3 Figure 1
Relation between annual decline in FEV1 and mean packs/day smoked between 1991 and 2002 from regression models 
reported in Table 3
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The distribution of years since quitting amongst men and
women quitters was similar and relatively short. Previous
studies have also reported attenuated effects from smok-
ing after short periods of cessation [7,27,28]. In the LHS,
the attenuation in lung function decline following smok-
ing cessation could be observed after one year [7]. The sig-
nificance of the difference in effect from packs smoked per
day between women quitters and persistent smokers was
marginal (p = 0.05), but increased with adjustment for
years since quitting; consistent with a recovery effect
related to quitting. We did not observe an attenuated
effect on lung function decline following smoking cessa-
tion in men, which has been reported elsewhere [7,29].
However, the number of quitters in our study was
relatively small and in the Tucson Epidemiological Study
of Airways Obstructive Disease, recovery in men was
restricted to young men with no evidence of airway
obstruction [29]. Our data provide additional evidence
that facility for recovery following smoking cessation is,
overall, greater in women compared to men.
Reliability of reporting habits may differ between sexes
and we are unable to assess the possible extent of this bias
in our study. However, we attempted to validate smoking
status using expired CO and similar proportions of men
and women were shown to have reported of inconsistent
information about smoking habits. In the ECRHS women
were as likely as men to report cough and phlegm but sig-
nificantly less likely to have airflow obstruction [30]. If
perception of decline in lung function is greater in women
than in men, susceptible women may be more likely to
quit smoking than susceptible men.
Evidence for a larger effect from smoking in men with
symptoms of obstructive airway disease was presented by
Fletcher and Peto almost 30 years ago [31]. Our data
showed that both women and men with a reduced FEV1/
FVC experienced an accelerated decline in FEV1 associated
with recent cigarette smoking but the effect was signifi-
cantly greater in women. We are unaware of other studies
showing an accelerated effect in lung function decline
related to smoking in women with obstructed airways
compared to men. However, the female predominance in
the Boston Early-Onset COPD Study has been attributed
to a higher risk for the development of severe COPD in
women compared to men [32]. Men and women persist-
ent smokers in the LHS study have been reported to be
approximately equivalent in terms of their percent pre-
dicted lung function loss [7]. However, since all LHS par-
ticipants had evidence of mild to moderate airway
obstruction at study entry, we would predict a sex differ-
ence in lung function decline per pack of cigarette
smoked.
Reduced flow rates are due to a combination of airway
narrowing and decreased lung recoil [9]. Predisposition to
airway narrowing and decreased lung recoil may vary
between men and women given sex differences in lung
characteristics [15]. In addition, experimental evidence
suggests that the distribution of particle deposition in the
airways is likely to be more proximal in women compared
to men [14]. Since airway caliber is smaller in women, we
could hypothesise that the same reduction in airway
diameter would result in a relatively greater impact on the
reduction in flow rates in women compared to men
[15,33].
An accelerated rate of lung function decline has also been
reported amongst asthmatics who smoke [34]. Excluding
women with bronchial hyperresponsiveness from our
population sample did not reduce the estimates for the
effect of packs/day on decline in FEV1 (data not shown).
Therefore, although asthmatics may well have experi-
enced an accelerated lung function decline it seems
unlikely that asthma per se is an explanation for the dif-
ferent rates of decline between men and women with a
reduced FEV1/FVC. Our findings suggest that smokers
with pre-existing airway obstruction are likely to experi-
ence accelerated lung function decline irrespective of the
potential underlying disease.
Conclusion
Some of the inconsistent findings from earlier studies
comparing effects from smoking on lung function
between men and women may be due to difficulties in
separating out effects from recent smoking and past smok-
ing. In both men and women recent smoking is a much
stronger predictor of lung function decline than smoking
more than 10 years previously. Our findings suggest that
women recover faster from past smoking than men, but
are particularly susceptible to effects from current
smoking when they have existing airways obstruction.
This observational study over 11 years suggests that
women should have even greater incentives, in terms of
lung function, to quit smoking than men.
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